Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Cancer immunotherapy has made remarkable strides in recent years, largely driven by the understanding of how immune cells, particularly dendritic cells (DCs), can be harnessed to target and eliminate cancer cells. A central challenge in cancer immunotherapy is ensuring that the immune system can recognize and respond to the full spectrum of tumor antigens, especially those that are intracellular in nature. Traditional cancer vaccines often present only surface-level antigens, which may not be sufficient for triggering a broad and effective immune response.
Tumor RNA Pulsed Dendritic Cell (DC) Development Service offers a unique solution by utilizing tumor-derived RNA to load dendritic cells, enabling them to present a wide array of intracellular tumor antigens. By harnessing this method, we can tap into the potential of previously hidden antigens—those found within the tumor cells themselves. This process enables the dendritic cells to stimulate a more robust immune response by activating both CD8+ cytotoxic T cells and CD4+ helper T cells, resulting in enhanced tumor recognition and destruction.
At Creative Biolabs, we offer Tumor RNA Pulsed Dendritic Cell (DC) Development Services designed to provide an optimal strategy for activating the immune system using tumor RNA, ensuring comprehensive antigen presentation and a more potent, targeted immune response against cancer.
Our Tumor RNA Pulsed Dendritic Cell (DC) Development Service combines the powerful antigen-presenting capabilities of dendritic cells with the diverse tumor-specific antigens contained in tumor RNA. By introducing tumor RNA into dendritic cells, we effectively enable these cells to present a broader spectrum of tumor antigens, including those that are typically difficult to access via conventional methods.
Key steps involved in our service include:
Tumor RNA is isolated from patient-derived tumor samples or allogeneic tumor cell lines. This RNA contains a diverse array of tumor-associated antigens, including both surface and intracellular proteins, that are essential for immune recognition and targeting.
Dendritic cells are isolated from the patient's peripheral blood or from other immune cell sources and cultured under specific conditions to ensure they mature into potent antigen-presenting cells. These mature dendritic cells are prepared to process and present a wide range of antigens to T cells.
The tumor RNA is introduced into the dendritic cells through advanced methods, ensuring efficient uptake and processing of the RNA. The dendritic cells internalize the RNA and begin presenting the tumor-specific antigens to T cells.
After the pulsing process, the dendritic cells are thoroughly validated to ensure they are effectively presenting a wide range of tumor antigens. The functionality of the dendritic cells is assessed through T-cell activation assays to confirm their ability to trigger a robust immune response.
The service can be customized to match the unique characteristics of the patient's tumor. This ensures that the dendritic cells are presenting the most relevant and effective tumor antigens, leading to a more targeted immune response.
By using tumor RNA, this service enables dendritic cells to present a broad array of tumor-associated antigens, including those that are normally difficult for the immune system to detect. This increases the likelihood of activating a more comprehensive immune response.
The RNA pulsing method activates both CD8+ cytotoxic T cells and CD4+ helper T cells, ensuring a well-rounded immune response that targets both the tumor cells directly and supports overall immune system activation.
The service can be customized to the individual tumor profile of the patient, ensuring that the dendritic cells present the most relevant tumor antigens, thereby optimizing the therapeutic effect.
Tumor RNA contains both surface and intracellular tumor antigens, providing a more comprehensive antigen presentation. This broadens the immune response and enhances the immune system's ability to target diverse tumor antigens.
Creative Biolabs uses advanced techniques and years of expertise in immuno-oncology to deliver high-quality, reliable services. We ensure that each step of the process, from RNA extraction to dendritic cell maturation, meets the highest standards.
Q1. Why is RNA used in this service instead of other antigen sources?
A1: RNA contains a comprehensive profile of both surface and intracellular tumor-associated antigens. This allows dendritic cells to present a broad range of antigens, including those that are typically inaccessible by traditional antigen presentation methods.
Q2. How do dendritic cells contribute to cancer immunotherapy?
A2: Dendritic cells are the most potent antigen-presenting cells in the immune system. When loaded with tumor antigens, they effectively activate T-cells, which in turn target and eliminate cancer cells. This service ensures a more robust immune response by presenting a wider array of tumor antigens.
Q3. Can this service be customized for different tumor types?
A3: Yes, our service is fully customizable. We tailor the RNA loading process based on the specific characteristics of the tumor, ensuring that the dendritic cells present the most relevant and effective antigens for the patient's cancer.
At Creative Biolabs, we are dedicated to advancing cancer immunotherapy through cutting-edge techniques like our Tumor RNA Pulsed Dendritic Cell (DC) Development Service. If you would like to learn more about how this service can be applied to your cancer research or therapy development, please contact us today.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
